N
CADX

Natixis’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Natixis’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-11,400
Closed -$105K – 645
2013
Q4 		$105K Buy
11,400
+500
+5% +$3.61K ﹤0.01% 498
2013
Q3 		$69K Buy
+10,900
New +$69.3K ﹤0.01% 461

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Natixis's CADX Position: Q1 2014 in Review

Natixis sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 11,400 shares — an estimated $105K sold.

Natixis first reported a position in CADX in Q3 2013 and held it in 2 quarters. The position peaked at $105K in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Natixis reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Natixis sold 11,400 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $105K.
  • Natixis first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q3 2013 and held it in 2 quarters.
  • Natixis's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $105K in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Natixis's 13F filing for Q1 2014, filed 14 May 2014.